Equities research analysts expect Hill-Rom Holdings, Inc. (NYSE:HRC) to report sales of $707.80 million for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Hill-Rom’s earnings, with the highest sales estimate coming in at $716.20 million and the lowest estimate coming in at $702.60 million. Hill-Rom posted sales of $710.50 million in the same quarter last year, which suggests a negative year-over-year growth rate of 0.4%. The business is expected to announce its next earnings results before the market opens on Friday, April 26th.
According to Zacks, analysts expect that Hill-Rom will report full year sales of $2.88 billion for the current year, with estimates ranging from $2.87 billion to $2.89 billion. For the next financial year, analysts expect that the company will post sales of $2.98 billion, with estimates ranging from $2.96 billion to $3.00 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Hill-Rom.
Hill-Rom (NYSE:HRC) last issued its quarterly earnings data on Friday, January 25th. The medical technology company reported $1.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.98 by $0.04. The business had revenue of $683.50 million for the quarter, compared to the consensus estimate of $676.39 million. Hill-Rom had a return on equity of 21.23% and a net margin of 7.21%. The firm’s revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.92 EPS.
HRC has been the topic of several research analyst reports. ValuEngine raised Hill-Rom from a “hold” rating to a “buy” rating in a research note on Saturday, January 19th. Zacks Investment Research reaffirmed a “buy” rating and set a $101.00 price objective on shares of Hill-Rom in a research note on Monday, December 31st. Needham & Company LLC reaffirmed a “buy” rating and set a $116.00 price objective on shares of Hill-Rom in a research note on Monday, March 11th. Barclays raised their price objective on Hill-Rom from $103.00 to $108.00 and gave the stock an “equal weight” rating in a research note on Monday, April 15th. Finally, Morgan Stanley dropped their price target on Hill-Rom from $100.00 to $98.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Hill-Rom currently has a consensus rating of “Buy” and a consensus target price of $109.88.
Hill-Rom stock traded up $0.87 during mid-day trading on Monday, hitting $97.13. 686,911 shares of the company’s stock were exchanged, compared to its average volume of 526,735. The company has a market capitalization of $6.40 billion, a PE ratio of 20.45, a PEG ratio of 1.66 and a beta of 0.95. Hill-Rom has a fifty-two week low of $81.82 and a fifty-two week high of $108.68. The company has a current ratio of 1.70, a quick ratio of 1.25 and a debt-to-equity ratio of 1.17.
The company also recently declared a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 22nd were paid a $0.21 dividend. This is an increase from Hill-Rom’s previous quarterly dividend of $0.20. The ex-dividend date was Thursday, March 21st. This represents a $0.84 annualized dividend and a dividend yield of 0.86%. Hill-Rom’s dividend payout ratio (DPR) is currently 17.68%.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its holdings in shares of Hill-Rom by 3.5% during the fourth quarter. BlackRock Inc. now owns 6,350,899 shares of the medical technology company’s stock worth $562,371,000 after buying an additional 215,770 shares in the last quarter. Vanguard Group Inc. raised its stake in Hill-Rom by 0.6% during the third quarter. Vanguard Group Inc. now owns 5,916,827 shares of the medical technology company’s stock valued at $558,549,000 after purchasing an additional 34,369 shares in the last quarter. Vanguard Group Inc raised its stake in Hill-Rom by 0.6% during the third quarter. Vanguard Group Inc now owns 5,916,827 shares of the medical technology company’s stock valued at $558,549,000 after purchasing an additional 34,369 shares in the last quarter. Oregon Public Employees Retirement Fund raised its stake in Hill-Rom by 8,755.0% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 2,308,056 shares of the medical technology company’s stock valued at $26,000 after purchasing an additional 2,281,991 shares in the last quarter. Finally, Fisher Asset Management LLC raised its stake in Hill-Rom by 0.6% during the fourth quarter. Fisher Asset Management LLC now owns 1,313,512 shares of the medical technology company’s stock valued at $116,311,000 after purchasing an additional 7,808 shares in the last quarter. 85.17% of the stock is currently owned by hedge funds and other institutional investors.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Read More: What is a Buy-Side Analyst?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.